Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus lenvatinib or sorafenib versus lenvatinib or sorafenib alone in unresectable hepatocellular carcinoma after prior atezolizumab plus bevacizumab
CTR20212957Phase 3Active
- Sponsor
- Roche
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab, lenvatinib, sorafenib in hepatocellular carcinoma (HCC), sponsored by Roche. Started Apr 2022; status: active.
02
Drugs
atezolizumablenvatinibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20212957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212957.